Across TCGA pan-cancer cohorts, PDCD1LG2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDCD1LG2 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PDCD1LG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD1LG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, THCA, and UCEC are the cancer types where PDCD1LG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.377	0.872	<.001	39	view →
THCA	DFS	Median	All	0.038	0.841	<.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.037	12	view →
SKCM	OS	Median	All	0.378	0.788	.009	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PDCD1LG2 tumor-vs-normal RNA expression · all PDCD1LG2 data types